NewLink Genetics Corp. NLNK, -42.62% plans to review its clinical programs after the failure of a similar drug in a Merck MRK, -2.15% and Incyte INCY, -22.93% clinical trial. NewLink noted that the mechanism of its drug, an IDO pathway inhibitor called indoximod, was different from other such products but said that it will nonetheless conduct a clinical program review because of the Incyte news. NewLink shares plummeted nearly 45% in Friday trade after Merck and Incyte said a trial testing their two drugs in combination did not meet its primary endpoint and that they are stopping the trial. NewLink shares have dropped nearly 55% over the last three months to $4.09, compared with a 5.4% drop in the S&P 500 SPX, -2.19%